PRINCIPALS
CARSTEN BEITH
Founder & Managing Member
Carsten Beith is the founder of Beith Capital Advisory, LLC (BCA), launched in 2023 to provide strategic and capital advisory services to start-up and early-growth stage companies working to improve the cost, quality, and access to healthcare in the U.S. and globally. BCA also advises health systems and large physician groups on strategic transactions and capital-related initiatives.
Prior to founding BCA, Carsten served as Vice Chairman at Cain Brothers, a division of KeyBanc Capital Markets. At Cain Brothers, he led the health systems M&A practice and advised on many of the largest and most complex transactions in the not-for-profit healthcare sector. He brings over 25 years of investment banking experience, with deep expertise in mergers and acquisitions, capital strategy, and corporate finance.
Carsten is widely recognized for his thought leadership in healthcare M&A and frequently writes and speaks on topics related to strategic capital formation and healthcare innovation.
Dr. ENRICO PETRILLO
Expert in Residence
Dr. Petrillo is an international leader in healthcare innovation in life sciences and IT with decades of experience as a venture capitalist, strategy consultant, academic physician, founder, and national policy advisor. He is director of international research programs and strategic initiatives for Harvard's flagship teaching hospital, Brigham and Women’s Hospital (BWH), and senior advisor to the Chair Dept. of Medicine and Physician-in-Chief. He is a faculty lecturer at Harvard Medical School, principal investigator in the Dept. of Medicine, and faculty-affiliated researcher at the Karolinska Institutet Sweden.
Enrico co-founded two early-stage institutional venture capital firms, with multiple funds under management totaling several hundred million dollars each. Representative investments include global leading platforms in cancer diagnostics and screening, precision cancer therapeutics, Life Sciences tools, healthcare cybersecurity, health and wellbeing, transplantation, women's health, and Healthcare IT. During his tenure at Fletcher Spaght Inc. (FSI), a Boston Consulting Group spin-out specializing in innovation and technology advice, Enrico led the initiation and development of world-leading innovation centers for Harvard teaching hospitals BWH and Boston Children’s Hospital. He consummated multiple high-profile technology transfer transactions, Including the commercialization of the world’s first cancer portfolio of cancer angiogenesis therapies, including Thalidomide, leading to Celgene being acquired by Bristol M Squibb for $69B; this breakthrough has spawned an entire leading field of cancer treatments worldwide.
Enrico has served as a national policy advisor to United States presidential candidates, senate members, and governmental agencies.